-+ 0.00%
-+ 0.00%
-+ 0.00%

*Neurocrine: Ingreza 2026 Net Sales Guidance Raised to $2.9B to $2.925B >NBIX

Dow Jones·11/02/2026 21:51:00

Please log in to view news